MX2010005395A - Metodo para tratar artritis. - Google Patents

Metodo para tratar artritis.

Info

Publication number
MX2010005395A
MX2010005395A MX2010005395A MX2010005395A MX2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A MX 2010005395 A MX2010005395 A MX 2010005395A
Authority
MX
Mexico
Prior art keywords
treating arthritis
arthritis
treating
preventing
disclosed
Prior art date
Application number
MX2010005395A
Other languages
English (en)
Spanish (es)
Inventor
Tariq Ghayur
Philip Bardwell
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010005395A publication Critical patent/MX2010005395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
MX2010005395A 2007-11-16 2008-11-14 Metodo para tratar artritis. MX2010005395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
PCT/US2008/083478 WO2009064938A1 (en) 2007-11-16 2008-11-14 Method of treating arthritis

Publications (1)

Publication Number Publication Date
MX2010005395A true MX2010005395A (es) 2010-06-02

Family

ID=40291332

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010005395A MX2010005395A (es) 2007-11-16 2008-11-14 Metodo para tratar artritis.

Country Status (14)

Country Link
US (2) US20090176785A1 (enExample)
EP (1) EP2231159A1 (enExample)
JP (2) JP5450434B2 (enExample)
KR (1) KR101585848B1 (enExample)
CN (1) CN101969951B (enExample)
AU (1) AU2008322595B2 (enExample)
CA (1) CA2705294C (enExample)
DO (1) DOP2013000169A (enExample)
IL (2) IL205501A (enExample)
MX (1) MX2010005395A (enExample)
NZ (2) NZ601350A (enExample)
RU (2) RU2526201C2 (enExample)
WO (1) WO2009064938A1 (enExample)
ZA (1) ZA201003434B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
BR112012024382A2 (pt) 2010-03-25 2017-08-08 Abbvie Inc agentes que induzem apoptose para o tratamento de câncer e doenças imunes e autoimunesças
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
MX349533B (es) 2010-10-29 2017-08-02 Abbvie Inc Dispersiones solidas que contienen un agente inductor de apoptosis.
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
NZ610151A (en) 2010-11-23 2015-06-26 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
MY191300A (en) 2010-11-23 2022-06-14 Abbvie Ireland Unlimited Co Methods of treatment using selective bcl-2 inhibitors
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
EP3672976B1 (en) 2017-08-23 2023-12-13 Guangzhou Lupeng Pharmaceutical Company Ltd. Bcl-2 inhibitors
WO2020041406A1 (en) 2018-08-22 2020-02-27 Newave Pharmaceutical Inc. Bcl-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
PH12022551091A1 (en) 2019-11-05 2024-06-24 Abbvie Deutschland Dosing regimens for use in treating myelofibrosis and mpn-related disorders with navitoclax
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
WO2021173523A1 (en) 2020-02-24 2021-09-02 Newave Pharmaceutical Inc. Hot melt extruded solid dispersions containing a bcl2 inhibitor
US20240166646A1 (en) 2020-12-22 2024-05-23 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
JP3020612B2 (ja) * 1995-10-10 2000-03-15 ファイザー インク． ロイコトリエンアンタゴニストとしてのインドールカルバメート類
BR0109328A (pt) * 2000-03-21 2003-06-10 Procter & Gamble Inibidores de metaloprotease n-substituìdos, contendo cadeia lateral heterocìclica
EP1506962B1 (en) * 2000-10-20 2008-07-02 Eisai R&D Management Co., Ltd. Nitrogen-containing aromatic heterocycles
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
AU2004261628B2 (en) * 2003-07-28 2011-05-12 Janssen Pharmaceutica N.V. Benzimidazole, benzthiazole and benzoxazole derivatives and their use as LTA4H modulators
KR100747401B1 (ko) * 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
PL1888550T3 (pl) * 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Also Published As

Publication number Publication date
NZ601350A (en) 2013-08-30
JP2011503199A (ja) 2011-01-27
RU2010123796A (ru) 2011-12-27
IL227641A0 (en) 2013-09-30
US20090176785A1 (en) 2009-07-09
DOP2013000169A (es) 2013-12-15
RU2526201C2 (ru) 2014-08-20
IL205501A (en) 2013-08-29
RU2012143212A (ru) 2014-04-20
AU2008322595B2 (en) 2014-01-30
WO2009064938A1 (en) 2009-05-22
JP2014065716A (ja) 2014-04-17
AU2008322595A1 (en) 2009-05-22
EP2231159A1 (en) 2010-09-29
CN101969951B (zh) 2012-10-31
KR101585848B1 (ko) 2016-01-15
ZA201003434B (en) 2011-10-26
CA2705294C (en) 2016-05-17
CA2705294A1 (en) 2009-05-22
CN101969951A (zh) 2011-02-09
JP5450434B2 (ja) 2014-03-26
WO2009064938A9 (en) 2009-08-06
IL205501A0 (en) 2010-12-30
US20160101109A1 (en) 2016-04-14
NZ585085A (en) 2012-08-31
JP5667684B2 (ja) 2015-02-12
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20

Similar Documents

Publication Publication Date Title
MX2010005395A (es) Metodo para tratar artritis.
SG148142A1 (en) Aryloazol-2-yl cyanoethylamino compunds, method of making and method of using thereof
MX2010009765A (es) Moleculas pequeñas que contienen boro como agentes anti-inflamatorios.
MX2009009761A (es) Composiciones y estuches para tratamiento de la influenza.
PH12012500674A1 (en) Heterocyclic compounds useful as pdk1 inhibitors
MX2009005725A (es) Metodos y composiciones para tratamiento y monitoreo de tratamiento de trastornos asociados con il-13.
MX360301B (es) Moleculas pequeñas que contienen boro como agentes antiinflamatorios.
PH12013502230A1 (en) Multispecific antibodies
WO2009111676A8 (en) Boron-containing small molecules as anti-inflammatory agents
IN2012DN00572A (enExample)
PT2408718E (pt) Composição à base de hidróxido de cálcio, método para a sua produção e para a sua utilização para o tratamento de águas e lamas
MX2009004030A (es) Articulos antimicrobianos y metodos de fabricacion.
MY150600A (en) Use of opioid antagonists for treating urinary retention
IL200769A (en) A method for processing potash
MX341340B (es) Tratamiento con flama de substrato.
PL2133402T3 (pl) Sposób obróbki błota defekosaturacyjnego
TW200745059A (en) Sulfonyl-substituted bicyclic compounds as modulators of PPAR
MX2009001150A (es) Aditivo que contiene titanio.
EP2164515A4 (en) PROCESS FOR TREATING ATOPIC ECZEMA
PL2219452T3 (pl) Sposoby leczenia twardziny
BR112012003653A2 (pt) "método de tratar o câncer."
WO2011110367A3 (en) Method of screening for htra protease inhibitors useful for prophylaxis and therapy of a bacterial infection
PH12014500538A1 (en) Methods and compositions for treating leukemia
MX2012001875A (es) Proceso para la preparación de inhibidores de la catepsina s.
MY144317A (en) Treatment of polysilazane waste

Legal Events

Date Code Title Description
GB Transfer or rights

Owner name: ABBVIE INC.

FG Grant or registration